scispace - formally typeset
C

Chuanshu Huang

Researcher at New York University

Publications -  271
Citations -  14763

Chuanshu Huang is an academic researcher from New York University. The author has contributed to research in topics: Kinase & Signal transduction. The author has an hindex of 61, co-authored 263 publications receiving 12976 citations. Previous affiliations of Chuanshu Huang include Peking Union Medical College & Chinese Academy of Sciences.

Papers
More filters
Journal ArticleDOI

Carcinogenic effect of nickel compounds.

TL;DR: The present review summarizes the current knowledge on the molecular mechanisms of nickel carcinogenesis, with special emphasis on the role of nickel induced reactive oxygen species (ROS) and signal transduction pathways.
Journal Article

Essential Role of p53 in Phenethyl Isothiocyanate-induced Apoptosis

TL;DR: It is found that PEITC blocks tumor promoter-induced cell transformation in mouse epidermal JB6 cells, and this inhibitory activity on cell transformation is correlated with induction of apoptosis, which may be involved in its cancer chemopreventive activity.
Journal ArticleDOI

Nickel carcinogenesis: epigenetics and hypoxia signaling.

TL;DR: Newport Green, a dye that fluoresces when ionic nickel is bound, is shown to be consistent with previously published reports showing that short-term exposure of cells to crystalline nickel particles is able to epigenetically silence target genes placed near heterochromatin, and nickel compounds activate hypoxia signaling pathways.
Journal ArticleDOI

Inhibition of Activator Protein 1 Activity and Neoplastic Transformation by Aspirin

TL;DR: The JB6 mouse epidermal cell lines are used as an in vitro model for the study of tumor promotion and anti-tumor promotion to study the anti-carcinogenesis effect of aspirin at the molecular level.
Journal ArticleDOI

Cancer prevention with freeze-dried berries and berry components

TL;DR: Results from a toxicity study indicated that freeze-dried black raspberries are well tolerated in humans when administered orally for 7 days at a dose of 45 g per day, and several Phase IIa clinical trials are underway in patients at high risk for esophagus and colon cancer.